Actinium Pharmaceuticals (ATNM)
(Real Time Quote from BATS)
$8.12 USD
+0.30 (3.84%)
Updated Jun 17, 2024 10:22 AM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Actinium Pharmaceuticals, Inc. [ATNM]
Reports for Purchase
Showing records 81 - 93 ( 93 total )
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
We are transferring coverage of ATNM to Director of Research Jeff Martin and placing shares Under Review
Provider: Roth Capital Partners, Inc.
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
Healthcare - Healthcare Monthly Catalyst Tracker; Does The Election Matter to Biotech?
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
Healthcare: Inaugural Healthcare Monthly; Catalysts Galore
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
Actimab-A Phase II Gets Going; Initial Data Not Too Far Off
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
Healthcare - The A to Z of HSCT: Investor?s guide to Hematopoietic Transplant Medicine
Provider: Roth Capital Partners, Inc.
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
Totally Rad Man; Providing More AML and Beyond Options; Initiating at Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
Initiation of Coverage - Totally Rad Man; Providing More AML and Beyond Options; rating with Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
Encouraging Phase 1 Data Defines Next Step in AML Program
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A